Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Veletri in PAH
NCT01470144Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2011
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jun 2011; status: completed.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01470144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470144.